Search
Phentermine
go.drugbank.com/drugs/DB00191ApprovedIllicitInvestigationalPhentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug. It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phenterm...
Azilsartan medoxomil
go.drugbank.com/drugs/DB08822ApprovedInvestigationalAzilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relativ...
Poloxamer 188
go.drugbank.com/drugs/DB11333ApprovedDue to its sufactant properties, P188 may also be found in over-the-counter (OTC) products such as toothpaste, laxatives and mouthwash, and used in various cosmetic, industrial and pharmaceutical applications
Alteplase
go.drugbank.com/drugs/DB00009ApprovedInvestigationalHowever, its use for the treatment of acute ischemic stroke (AIS) has increased over the years.
Methimazole
go.drugbank.com/drugs/DB00763ApprovedInvestigational[A184733] Traditionally, methimazole has been preferentially used over propylthiouracil due to the risk of fulminant hepatotoxicity carried by the latter,[A184757] with propylthiouracil being preferred
Buspirone
go.drugbank.com/drugs/DB00490ApprovedInvestigationalBuspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT1A receptor agonist that is not chemically or pharmacologically re...
Gavestinel
go.drugbank.com/drugs/DB06741ExperimentalGavestinel displays > 1000-fold selectivity over NMDA, AMPA and kainate binding sites and is orally bioavailable and active in vivo.
NGD-4715
go.drugbank.com/drugs/DB06027ExperimentalNGD-4715 is an investigational compound developed for the treatment of Obesity. NGD-4715 functions as a melanin-concentrating hormone receptor 1 antagonist.
Ustekinumab
go.drugbank.com/drugs/DB05679ApprovedInvestigational[A187346] The therapeutic use of the drug started in Canada, the US, and Europe since 2009 when it was first approved for the treatment of adult patients with moderate to severe plaque psoriasis and
JSM 6427
go.drugbank.com/drugs/DB06139InvestigationalIt has been biologically validated for therapeutic use in the prevention and treatment of wet AMD, the leading cause of blindness in people over the age of 55.